The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Abstract

The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFN beta)-1a in patients with relapsing multiple sclerosis (MS).

Keywords

• Multiple sclerosis
• natalizumab
• interferon beta-1a
• subgroup analysis
• highly active relapsing multiple sclerosis
• placebo-controlled trial
• double-blind
• interferon beta-1a
• predictive value
• natural-history
• disability
• integrin
• multicenter
• pathogenesis
• progression